H.C. Wainwright reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a price target of $21.00. Comments follow news ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE